CD4 T cells in tumor immunity

被引:102
作者
Gerloni, M
Zanetti, M
机构
[1] Univ Calif San Diego, Dept Med, Immunol Lab, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA
来源
SPRINGER SEMINARS IN IMMUNOPATHOLOGY | 2005年 / 27卷 / 01期
关键词
tumor immunity; CD4 T cells; MHC class II; Th-Th cell cooperation;
D O I
10.1007/s00281-004-0193-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in protective anti-tumor responses has received growing attention. Here we will discuss the role of MHC class II-restricted T cells in response to, and in the regulation of, tumor antigens. Emphasis will be placed on four areas: (1) the role of CD4 T cell immunity in tumor protection in animal models and putative mode of action, (2) tumor antigens recognized by human CD4 T cells, (3) the cooperation between two CD4 T cells of different specificity as a new way to jump start the response against sub-immunogenic determinants of tumor antigens in a tolerant environment, and (4) the negative impact of regulatory CD4 T cells on anti-tumor T cell responses. By drawing attention to these four areas, it is our intention to provide the reader with a comprehensive view of issues of contemporary importance for this field, in the expectation that the information will help a better design of therapeutic cancer vaccines.
引用
收藏
页码:37 / 48
页数:12
相关论文
共 82 条
[1]
A THEORY OF SELF-NONSELF DISCRIMINATION [J].
BRETSCHER, P ;
COHN, M .
SCIENCE, 1970, 169 (3950) :1042-+
[2]
Burnet F M, 1971, Transplant Rev, V7, P3
[3]
Campi G, 2003, CANCER RES, V63, P8481
[4]
Reviving suppression? [J].
Cantor, H .
NATURE IMMUNOLOGY, 2004, 5 (04) :347-349
[5]
Type 1 and Type 2: A fundamental dichotomy for all T-cell subsets [J].
Carter, LL ;
Dutton, RW .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (03) :336-342
[6]
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes [J].
Chaux, P ;
Vantomme, V ;
Stroobant, V ;
Thielemans, K ;
Corthals, J ;
Luiten, R ;
Eggermont, AMM ;
Boon, T ;
van der Bruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05) :767-777
[7]
Chikamatsu K, 2003, CANCER RES, V63, P3675
[8]
Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8 [J].
Cobbold, SP ;
Adams, E ;
Marshall, SE ;
Davies, JD ;
Waldmann, H .
IMMUNOLOGICAL REVIEWS, 1996, 149 :5-33
[9]
Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis [J].
Coughlin, CM ;
Salhany, KE ;
Gee, MS ;
LaTemple, DC ;
Kotenko, S ;
Ma, XJ ;
Gri, G ;
Wysocka, M ;
Kim, JE ;
Liu, L ;
Liao, F ;
Farber, JM ;
Pestka, S ;
Trinchieri, G ;
Lee, WMF .
IMMUNITY, 1998, 9 (01) :25-34
[10]
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949